ScoreComparison
Why is Amicus Therapeutics, Inc. ?
1
The company has declared Positive results for the last 6 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 33.14 MM
- NET PROFIT(HY) Higher at USD 19 MM
- ROCE(HY) Highest at -11.58%
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 65.82%, its profits have risen by 84.9%
3
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
4
Market Beating Performance
- The stock has generated a return of 65.82% in the last 1 year, much higher than market (S&P 500) returns of 13.68%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Amicus Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Amicus Therapeutics, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Amicus Therapeutics, Inc.
66.05%
0.90
47.96%
S&P 500
13.68%
0.71
19.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
19.51%
EBIT Growth (5y)
16.31%
EBIT to Interest (avg)
-4.28
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.77
Sales to Capital Employed (avg)
0.83
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
2.79%
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
19.58
EV to EBIT
134.69
EV to EBITDA
110.38
EV to Capital Employed
12.66
EV to Sales
7.77
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
9.40%
ROE (Latest)
-5.36%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend16What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 33.14 MM
NET PROFIT(HY)
Higher at USD 19 MM
ROCE(HY)
Highest at -11.58%
DEBT-EQUITY RATIO
(HY)
Lowest at 54.27 %
NET SALES(Q)
Highest at USD 185.21 MM
-9What is not working for the Company
PRE-TAX PROFIT(Q)
At USD 3.14 MM has Fallen at -60.39%
NET PROFIT(Q)
At USD 1.69 MM has Fallen at -88.53%
INVENTORY TURNOVER RATIO(HY)
Lowest at 0.46 times
Here's what is working for Amicus Therapeutics, Inc.
Operating Cash Flow
Highest at USD 33.14 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
Highest at USD 185.21 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Debt-Equity Ratio
Lowest at 54.27 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Here's what is not working for Amicus Therapeutics, Inc.
Pre-Tax Profit
At USD 3.14 MM has Fallen at -60.39%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (USD MM)
Net Profit
At USD 1.69 MM has Fallen at -88.53%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
Inventory Turnover Ratio
Lowest at 0.46 times and Fallen
In each half year in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
